miDiagnostics selected to be part of Health innovation exchange program of UNAIDS

Leuven, Belgium   I   January 2020

 

While new solutions for health are emerging in different parts of the world, these do not always get adopted on scale to deliver impact. There is a disconnect between innovators and implementers that needs to be bridged.

UNAIDS and partners have launched a new initiative to leverage the potential of innovations to improve the health of all.

The Health Innovation Exchange identifies challenges faced by implementers and connects them with innovations that have high potential for impact. It also links with investors to scale up the efforts and develop sustainable solutions.

The Health Innovation Exchange builds upon and shares the expertise of countries, global health actors, innovators, communities and the private sector.

It is founded on a shared commitment to leave no one behind in our journey to achieve the SDGs.

Share this story

 

About miDIAGNOSTICS

miDiagnostics is using silicon chip technology which will bring miniaturized, rapid, easy-to-use, lab-quality tests with built-in connectivity direct to the patient and clinician.
Combining a nanofluidic processor on a chip and a compact reader, miDiagnostics can measure virtually any biomarker from an easily accessed sample such as drops of fingerprick blood. The Company is developing an extensive portfolio of tests for screening, diagnosis and monitoring of a wide range of health conditions, including infectious diseases.
Spun out of the world-leading R&D and innovation hub in nanoelectronics and digital technologies, imec, and a research collaboration with Johns Hopkins University, the leading US research and medical centre, miDiagnostics’ goal is to enable fast, comprehensive and cost-effective health analysis, regardless of location.  Based in Leuven, Belgium, miDiagnostics is a privately held company created in 2015.
Learn More

Share This

Copy Link to Clipboard

Copy